Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial
(NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of TALZENNA ® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor,
In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate ...
The overall survival data from the late-stage trial will help Pfizer in its bid to expand the label for Talzenna and Xtandi, ...
Pfizer said on Thursday a combination of its drugs, Talzenna and Xtandi, helped prolong the lives of patients with a type of ...
US pharma giant Pfizer today released positive top line results from the final prespecified overall survival (OS) analysis of ...
According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback